Cargando…

Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial

BACKGROUND: The prevalence of type 2 diabetes (T2D) continues to rise in the United States and worldwide. Cognitive behavioral therapy (CBT) has been shown to improve glycemic control in patients with T2D, but broad implementation has been limited by inherent access and resource constraints. Digital...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canonico, Mario Enrico, Hsia, Judith, Guthrie, Nicole L., Simmons, Martha, Mehta, Prapti, Lupinacci, Paul, Edwards, Kate, Mosesso, Kara, Gearhart, Michelle, Skuban, Aleksandar, Bonaca, Marc P., Berman, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Clinical Study Design
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346968/ https://www.ncbi.nlm.nih.gov/pubmed/35778834 http://dx.doi.org/10.1002/clc.23853

Ejemplares similares

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial
por: Hess, Connie N., et al.
Publicado: (2022)

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
por: Sorbets, Emmanuel, et al.
Publicado: (2017)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)

Rate or Rhythm Control in CRT (RHYTHMIC): Study rationale and protocol
por: Elliott, Mark K., et al.
Publicado: (2022)

Rationale and design of the EMPYREAN study
por: Motoki, Hirohiko, et al.
Publicado: (2020)

Rationale and design of the AUGUST‐AHF Study
por: Zhang, Jingjing, et al.
Publicado: (2020)

Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study
por: Miyamoto, Satoshi, et al.
Publicado: (2022)

Mechanisms of Diuretic Resistance Study: design and rationale
por: Cox, Zachary L., et al.
Publicado: (2020)

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
por: Bain, Stephen C., et al.
Publicado: (2018)

Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes
por: Hsia, Judith, et al.
Publicado: (2022)

Rationale and Design of the PRegnancy and Infant DEvelopment (PRIDE) Study
por: van Gelder, Marleen M H J, et al.
Publicado: (2013)

The genomics of heart failure: design and rationale of the HERMES consortium
por: Lumbers, R. Thomas, et al.
Publicado: (2021)

Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry
por: Berman, Adam N., et al.
Publicado: (2020)

Kyoto Congestive Heart Failure (KCHF) study: rationale and design
por: Yamamoto, Erika, et al.
Publicado: (2017)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

The FOsmetpantotenate Replacement Therapy (FORT) randomized, double-blind, Placebo-controlled pivotal trial: Study design and development methodology of a novel primary efficacy outcome in patients with pantothenate kinase-associated neurodegeneration
por: Klopstock, Thomas, et al.
Publicado: (2019)

TranslatiOnal Registry for CardiomyopatHies (TORCH) – rationale and first results
por: Seyler, Claudia, et al.
Publicado: (2017)

Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy
por: Farrant, John, et al.
Publicado: (2023)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
por: Lainscak, Mitja, et al.
Publicado: (2019)

Rationale and design of the CardioMEMS Post‐Market Multinational Clinical Study: COAST
por: Cowie, Martin R., et al.
Publicado: (2020)

Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry
por: Shakoor, Abdul, et al.
Publicado: (2023)

Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial
por: Tajstra, Mateusz, et al.
Publicado: (2023)

Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study
por: Dauw, Jeroen, et al.
Publicado: (2021)

The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges
por: Eikelboom, John, et al.
Publicado: (2022)

Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF
por: Palazzuoli, Alberto, et al.
Publicado: (2017)

Rationale and design of the EU‐CERT‐ICD prospective study: comparative effectiveness of prophylactic ICD implantation
por: Zabel, Markus, et al.
Publicado: (2018)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
por: Wachter, Rolf, et al.
Publicado: (2020)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure
por: Krzesiński, Paweł, et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial
por: Hayer, Manvir K., et al.
Publicado: (2017)

Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial
por: Keene, Daniel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fetou1iklpsf03a2jhg3ocdqj5